Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Novavax Inc (NVAX)

Novavax Inc (NVAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,127,121
  • Shares Outstanding, K 140,404
  • Annual Sales, $ 983,710 K
  • Annual Income, $ -545,060 K
  • 60-Month Beta 1.63
  • Price/Sales 2.24
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NVAX with:

Options Overview Details

View History
  • Implied Volatility 103.14% ( -16.86%)
  • Historical Volatility 230.43%
  • IV Percentile 40%
  • IV Rank 51.13%
  • IV High 187.27% on 05/13/24
  • IV Low 15.11% on 11/28/23
  • Put/Call Vol Ratio 0.22
  • Today's Volume 39,998
  • Volume Avg (30-Day) 48,865
  • Put/Call OI Ratio 1.09
  • Today's Open Interest 395,081
  • Open Int (30-Day) 315,164

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.87
  • Number of Estimates 4
  • High Estimate -0.53
  • Low Estimate -1.23
  • Prior Year 0.58
  • Growth Rate Est. (year over year) -250.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.90 +297.44%
on 04/25/24
17.40 -10.92%
on 05/22/24
+11.35 (+273.49%)
since 04/24/24
3-Month
3.81 +306.82%
on 04/18/24
17.40 -10.92%
on 05/22/24
+10.21 (+193.01%)
since 02/23/24
52-Week
3.53 +338.80%
on 02/05/24
17.40 -10.92%
on 05/22/24
+8.21 (+112.62%)
since 05/24/23

Most Recent Stories

More News
Why Vaccine Stocks Rallied This Week

A bird flu outbreak could spur demand for vaccines from these key players, but is it likely?

SNY : 48.54 (-0.94%)
MRNA : 166.61 (+1.59%)
NVAX : 15.50 (+2.31%)
BNTX : 96.95 (-2.07%)
PFE : 28.88 (+0.66%)
Better Buy: Inovio Pharmaceuticals vs. Novavax

Both biotechs have been struggling for a while, but there might be some hope for them.

PFE : 28.88 (+0.66%)
NVAX : 15.50 (+2.31%)
INO : 11.00 (+0.36%)
3 Things You Need to Know If You Buy Novavax Today

The vaccine maker's recovery story is looking brighter.

SNY : 48.54 (-0.94%)
PFE : 28.88 (+0.66%)
NVAX : 15.50 (+2.31%)
This Stock Just More Than Doubled in 1 Day: Is It a Buy?

The biotech still hasn't lost momentum.

NVAX : 15.50 (+2.31%)
SNY : 48.54 (-0.94%)
Is Novavax Stock a Buy?

Can Novavax's stock continue soaring?

NVAX : 15.50 (+2.31%)
Could Novavax Become the Next Moderna?

Sanofi believes in Novavax's vaccine strengths...

SNY : 48.54 (-0.94%)
PFE : 28.88 (+0.66%)
NVAX : 15.50 (+2.31%)
MRNA : 166.61 (+1.59%)
If You'd Invested $10,000 in Novavax a Year Ago, This Is How Much You'd Have Now

This coronavirus vaccine maker entered the market behind rivals.

NVAX : 15.50 (+2.31%)
1 Wall Street Analyst Thinks Novavax Stock Is Going to $10. Is It a Sell?

A potentially very lucrative arrangement with a peer doesn't necessarily make the company a buy.

NVAX : 15.50 (+2.31%)
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now

These two healthcare stocks may be deeply undervalued.

ETN : 340.89 (+0.73%)
CPRX : 15.87 (-0.31%)
NVAX : 15.50 (+2.31%)
SNY : 48.54 (-0.94%)
Novavax Stock Just Tripled. Is It Too Late to Buy?

Novavax shares have soared and plummeted in recent years.

SNY : 48.54 (-0.94%)
NVAX : 15.50 (+2.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple...

See More

Key Turning Points

3rd Resistance Point 16.98
2nd Resistance Point 16.47
1st Resistance Point 15.99
Last Price 15.50
1st Support Level 14.99
2nd Support Level 14.48
3rd Support Level 13.99

See More

52-Week High 17.40
Last Price 15.50
Fibonacci 61.8% 12.10
Fibonacci 50% 10.47
Fibonacci 38.2% 8.83
52-Week Low 3.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar